Comprehensive and detailed guide on the topic ‘HAS Évaluation of Tirzépatide: Transparency Committee Opinion’: sourced medical information, practical recommendations, and expert advice for patients on GLP-1 treatment. Understanding the stakes The topic addressed in this article – HAS évaluation of tirzépatide: transparency committee opinion – … Read more
Comprehensive and detailed guide on ‘Osteoarthritis and Weight Loss with GLP-1s: Relieving Your Joints’: sourced medical information, practical recommendations, and expert advice for patients undergoing GLP-1 treatment. Understanding the stakes The topic addressed in this article – osteoarthritis and weight loss with GLP-1s: relieving your joints – … Read more
Comprehensive and detailed guide on ‘GLP-1 and Polycystic Ovary Syndrome (PCOS)’: sourced medical information, practical recommendations, and expert advice for patients undergoing GLP-1 treatment. Understanding the challenges The topic addressed in this article – GLP-1 and Polycystic Ovary Syndrome (PCOS) – is a major concern for patients undergoing … Read more
Tirzépatide significantly improves the lipid profile: lowering LDL, reducing triglycerides, and increasing HDL. Impact of tirzépatide on LDL cholestérol Tirzépatide reduces LDL-cholestérol by 5 to 10% on average in clinical trials. Although this reduction is modest compared to statins, it adds to the effects of the latter. … Read more
Mounjaro (tirzepatide) reduces blood pressure by an average of 5 to 8 mmHg, a clinically significant benefit for obese hypertensive patients. Hypertension and obesity: a vicious cycle. Obesity is a major risk factor for high blood pressure. Each 10 kg of excess weight increases systolic blood pressure by 3 to … Read more
Obesity promotes metabolic syndrome. GLP-1 agonists like tirzepatide simultaneously correct several components. Understanding Metabolic Syndrome Metabolic syndrome is defined by the presence of at least 3 of the following 5 criteria: waist circumference greater than 94 cm (men) or 80 cm (women), triglycerides greater than 1.5 g/L, HDL-cholesterol less than … Read more
Tirzepatide modifies the brain’s reward circuits involved in food addiction. This revolutionary discovery explains why many patients report a dramatic reduction in their compulsive cravings for food and even alcohol while on treatment. The Food Addiction Brain Food addiction shares neurobiological mechanisms with substance addictions. Ultra-processed foods … Read more
HIIT and moderate cardio offer complementary approaches for patients on tirzepatide. Choosing the right type of cardiovascular training depends on your treatment phase, physical condition, and body composition goals. HIIT vs moderate cardio: definitions and differences. HIIT (High-Intensity Interval Training) alternates phases of intense effort … Read more
Sarcopenia is the most underestimated risk of GLP-1 agonist treatments. This muscle wasting, accelerated by the caloric deficit of tirzepatide, can compromise long-term mobility and metabolism if not actively prevented. What is sarcopenia and why is it exacerbated under GLP-1? Sarcopenia refers to the loss … Read more
The Mediterranean diet represents the most well-documented dietary approach to complement tirzepatide treatment. Rich in anti-inflammatory foods and low in ultra-processed products, it optimizes the metabolic results of the treatment. Why the Mediterranean diet is ideal with tirzepatide The Mediterranean diet has been recognized by the WHO and the World Obesity Federation as the … Read more
Gastroparesis is a rare but potentially debilitating side effect of GLP-1 agonists. Here’s how to recognize and prevent it. Gastroparesis, defined by an abnormal slowing of gastric emptying without mechanical obstruction, has received considerable media attention with the rise of GLP-1 treatments. Although rare, this complication can be debilitating and … Read more
Hair loss with GLP-1 agonists is a concern for patients. Here’s what science really says about this phenomenon. Hair loss (alopecia) is a growing concern among patients on GLP-1 agonists, amplified by testimonials on social media. But what do scientific data really say? Is it a … Read more